Loading
A working committee sorted the confusing family of neuroendocrine prostate cancers into named categories, so that a few scattered stained cells would stop being reported in the same words as a small cell carcinoma.
A Prostate Cancer Foundation working committee on the molecular biology and pathologic classification of neuroendocrine differentiation in prostate cancer convened in July 2013, prompted by clinical and molecular data emerging from prostate cancers treated with contemporary androgen deprivation therapies as well as from primary lesions. The resulting classification comprises usual prostate adenocarcinoma with neuroendocrine differentiation; adenocarcinoma with Paneth cell neuroendocrine differentiation; carcinoid tumour; small cell carcinoma; large cell neuroendocrine carcinoma; and mixed neuroendocrine carcinoma with acinar adenocarcinoma. The article also highlights prostate carcinoma with overlapping features of small cell carcinoma and acinar adenocarcinoma, and castration-resistant prostate cancer with a small cell cancer-like clinical presentation.
It made the reporting of these tumours mean something. The distinction it draws is the one that changes treatment: a few chromogranin-positive cells in an ordinary adenocarcinoma is not the same event as a small cell carcinoma emerging under hormonal treatment, and only the second leads to platinum and etoposide.
Shares Treatment-emergent neuroendocrine transformation (recognising it), Histologic transformation, Neuroendocrine and small-cell prostate cancer, Lineage plasticity & neuroendocrine transformation.
Shares Treatment-emergent neuroendocrine transformation (recognising it), Histologic transformation, Neuroendocrine and small-cell prostate cancer, Lineage plasticity & neuroendocrine transformation.
Shares Histologic transformation, Neuroendocrine and small-cell prostate cancer, Lineage plasticity & neuroendocrine transformation, Castration-resistant prostate cancer (CRPC).
Shares Treatment-emergent neuroendocrine transformation (recognising it), Histologic transformation, Neuroendocrine and small-cell prostate cancer, Lineage plasticity & neuroendocrine transformation.
Shares Histologic transformation, Neuroendocrine and small-cell prostate cancer, Lineage plasticity & neuroendocrine transformation, Castration-resistant prostate cancer (CRPC).
Shares Treatment-emergent neuroendocrine transformation (recognising it), Histologic transformation, Neuroendocrine and small-cell prostate cancer, Lineage plasticity & neuroendocrine transformation.
Shares Treatment-emergent neuroendocrine transformation (recognising it), Histologic transformation, Neuroendocrine and small-cell prostate cancer, Lineage plasticity & neuroendocrine transformation.
Shares Histologic transformation, Neuroendocrine and small-cell prostate cancer, Lineage plasticity & neuroendocrine transformation, Castration-resistant prostate cancer (CRPC).